Keros Therapeutics (NASDAQ:KROS) Lowered to Neutral Rating by Cantor Fitzgerald

Cantor Fitzgerald cut shares of Keros Therapeutics (NASDAQ:KROS - Free Report) from an overweight rating to a neutral rating in a research note issued to investors on Tuesday, MarketBeat.com reports.

A number of other equities research analysts also recently issued reports on the stock. TD Cowen downgraded shares of Keros Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Wedbush cut shares of Keros Therapeutics from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $47.00 to $15.00 in a research report on Friday. Oppenheimer dropped their target price on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. Wells Fargo & Company lifted their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a research note on Friday. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $52.56.

Keros Therapeutics Price Performance

Keros Therapeutics stock traded up $0.61 during trading hours on Tuesday, hitting $11.47. The company had a trading volume of 1,803,920 shares, compared to its average volume of 2,532,369. The firm has a 50-day moving average of $35.23 and a 200 day moving average of $46.97. The firm has a market cap of $464.65 million, a PE ratio of -2.19 and a beta of 1.43. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same period in the previous year, the firm posted ($1.33) earnings per share. The business's revenue for the quarter was up 4750.0% compared to the same quarter last year. As a group, research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Large investors have recently modified their holdings of the company. FMR LLC boosted its holdings in Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company's stock worth $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC lifted its position in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after buying an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. boosted its stake in shares of Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company's stock worth $68,772,000 after buying an additional 89,952 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP increased its position in shares of Keros Therapeutics by 22.5% during the third quarter. Holocene Advisors LP now owns 843,110 shares of the company's stock valued at $48,959,000 after acquiring an additional 154,784 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.